Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1Breast 1

Conditions

Melanoma 4Uveal Melanoma 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Sarcoma 1Osteosarcoma 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

tocilizumab 1poly ICLC 1pembrolizumab 1montanide ISA 51 1flt3 ligand protein 1cc-486 1Surveys and Questionnaires 1Standard of Care 1Radiotherapy 1Radiation 1Quality of Life 1Psychology, Positive 1Practice Guidelines as Topic 1Patient Reported Outcome Measures 1Palliative Care 1Observation 1Molecular Diagnostic Techniques 1Methods 1Interleukin-2 1Injections 1Immunotherapy 1Gemcitabine 1Etoposide 1Drug Therapy 1Cyclophosphamide 1Biological Therapy 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bone Neoplasms × tocilizumab × Dermatologic × Clear all
NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

University of Southern California

Phase 1 Active not recruiting
14 enrolled
BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡